Induction of MHC class I antigen expression following infection of a human esthesioneuroblastoma cell line with cytomegalovirus and human immunodeficiency virus.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Induction of MHC class I antigen expression following infection of a human esthesioneuroblastoma cell line with cytomegalovirus and human immunodeficiency virus.

Acta Virol. 1992 Dec;36(6):551-6. Unique Identifier : AIDSLINE MED/93318709
Mathiesen T; Collins VP; Ohlsson E; Sundqvist VA; Wahren B; Department of Neurosurgery, Karolinska Institute, Stockholm,; Sweden.

Abstract: Productive infections with cytomegalovirus (CMV) and human immunodeficiency virus (HIV) were established in the Tp41ON cell line derived from a human esthesioneuroblastoma. HIV antigen expression was highest in cultures coinfected with CMV and HIV. Viral infection caused increased MHC class I antigen expression while class II and CD4 antigens remained undetectable using immunofluorescence methods. Uninfected cultures showed 10% and coinfected cultures 80% class I antigen positive cells. In coinfected cultures, CMV and HIV antigens were detected in 4% and 8% of the cells, respectively. The detection of CMV antigens in some multinucleated cells suggests coinfection with both viruses in these cells, as multinucleated cells were not found in cultures infected with CMV only. The study shows that a cell line showing neuronal differentiation in vitro can be infected with CMV and HIV and that this infection increases MHC class I antigen expression.

Keywords: Antigens, CD4/ANALYSIS Antigens, Neoplasm/*BIOSYNTHESIS Antigens, Viral/BIOSYNTHESIS Cell Differentiation Cytomegalovirus/*PHYSIOLOGY Cytopathogenic Effect, Viral Gene Expression Regulation, Neoplastic Human HIV Antigens/BIOSYNTHESIS HIV-1/*PHYSIOLOGY HLA Antigens/*BIOSYNTHESIS HLA-D Antigens/ANALYSIS Neuroepithelioma/*IMMUNOLOGY/PATHOLOGY Tumor Cells, Cultured/IMMUNOLOGY/MICROBIOLOGY JOURNAL ARTICLE
931030
M93A0752

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .